Roivant Sciences price target raised to $26 from $22 at BofA

BofA raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $22 and keeps a Neutral rating on the shares. The fiscal Q3 print was in-line and the main update was positive Phase 2 topline results of brepocitinib in cutaneous sarcoidosis, notes the analyst, whose raised target reflects a higher brepo sales forecast given the positive results.